Αποτελέσματα Αναζήτησης
DESCRIPTION. ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE).
Generic Allegra-D Approved. A combination of fexofenadine HCl and pseudoephedrine HCl in an extended-re-lease tablet (60 mg/120 mg) is indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and chil-dren 12 years and older.
ORTHO EVRA® compared to women who used oral contraceptives containing 30-35 μg of ethinyl estradiol (EE) and either norgestimate (NGM) or levonorgestrel (LNG) has been estimated in three case control studies using electronic healthcare claims data derived from users in the USA. These studies (see Table 1.1), which used different
PRESCRIBING INFORMATION. ACTIVE INGREDIENT(S): Norelgestromin (NGMN) and ethinyl estradiol (EE). o Summary of Product Characteristics (SmPC) before pre. embolism (VTE), and how the risk of VTE with EVRA. compares with other CHCs (see contraindications and special warn. Adults: Transdermal use. One patc.
SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE MEDICINAL PRODUCT. EVRA 203 micrograms/24 hours + 33.9 micrograms/24 hours transdermal patch. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION. Each 20 cm2 transdermal patch contains 6 mg norelgestromin (NGMN) and 600 micrograms ethinyl estradiol (EE).
What EVRA is and what is it used for. ntains two types of sex hormones, a progestogen called norelgestromin and an oestrogen ca. c. ntains two hormones, EVRA is called a ‘. It is used to prevent pregnancy. 2. What you need to know before you use EVRA. General notes. y important to read the symptoms of a blood clot - see section 2 “Blo.
The EVRA (norelgestromin and ethinyl estradiol) transdermal system, with a contact surface area of 20 cm2, is a thin, matrix-type transdermal system consisting of three layers. Each transdermal system contains 6.0 mg norelgestromin and 0.60 mg ethinyl estradiol (EE).
